Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Director comp.
|
|
MoonLake Immunotherapeutics
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Bought 58,839 shares
@ $59.8973, valued at
$3.5M
|
|
| 10/04/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Bought 74,911 shares
@ $57.37, valued at
$4.3M
Bought 150,487 shares
@ $57.252, valued at
$8.6M
Bought 67,814 shares
@ $57.3188, valued at
$3.9M
|
|
| 10/03/2023 |
4
| Sturge Simon (Director) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Converted 342,980 shares
@ $0
Disposed/sold 342,980 shares
@ $0
Converted 10,196 options to buy
@ $0 |
|
| 10/03/2023 |
4
| Bodenstedt Matthias (CFO) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Converted 62,972 shares
@ $0
Disposed/sold 62,972 shares
@ $0
Converted 1,872 options to buy
@ $0 |
|
| 10/03/2023 |
4
| Santos da Silva Jorge (CEO) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Converted 3,027,483 shares
@ $0
Disposed/sold 3,027,483 shares
@ $0
Converted 140,071 shares
@ $0
Disposed/sold 140,071 shares
@ $0
Converted 90,000 options to buy
@ $0
Converted 4,164 options to buy
@ $0 |
|
| 10/03/2023 |
4
| Reich Kristian (Chief Scientific Officer) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Converted 2,527,477 shares
@ $0
Disposed/sold 2,527,477 shares
@ $0
Converted 41,981 shares
@ $0
Disposed/sold 41,981 shares
@ $0
Converted 75,136 options to buy
@ $0
Converted 1,248 options to buy
@ $0 |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Bought 800,000 shares
@ $50, valued at
$40M
|
|
| 06/30/2023 |
SC 13D/A
| BIOTECHNOLOGY VALUE FUND L P reports a 35.8% stake in MoonLake Immunotherapeutics |
| 06/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/28/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Bought 1,481 shares
@ $36.91, valued at
$54.7k
Bought 3,755 shares
@ $38.18, valued at
$143.4k
Bought 10,593 shares
@ $39.17, valued at
$414.9k
Bought 38,623 shares
@ $39.87, valued at
$1.5M
Bought 50,642 shares
@ $41.03, valued at
$2.1M
Bought 61,042 shares
@ $42.12, valued at
$2.6M
Bought 66,087 shares
@ $43.3, valued at
$2.9M
Bought 31,558 shares
@ $44.23, valued at
$1.4M
Bought 10,946 shares
@ $44.93, valued at
$491.8k
Bought 37,783 shares
@ $48.93, valued at
$1.8M
Bought 59,787 shares
@ $49.82, valued at
$3M
|
|
| 06/12/2023 |
4
| BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 06/12/2023 |
4
| Sturge Simon (Director) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 06/12/2023 |
4
| Xavier Ramnik (Director) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 06/12/2023 |
4
| Loy Spike (Director) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 06/12/2023 |
4
| Moukheibir Catherine (Director) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 06/12/2023 |
4
| Phillips Andrew John (Director) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/01/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/01/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
SC 13G
| Chen Bihua reports a 17.6% stake in MoonLake Immunotherapeutics |
| 03/28/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|
|
|